Thirty-one post-menopausal patients with advanced mammary carcinoma were treated with calusterone (7-beta, 17-alpha-dimethyl-testosterone), 200 mg daily per os for at least three months. Twenty-seven patients were evaluable. Eight patients (29%) had an objective response; two patients had a complete remission, maintained for more than eighteen months by repeated three-month courses of therapy. In eight patients (29%), calusterone produced no objective response, without disease progression. The main side effects have been hirsutism, acne and gastro-intestinal distress; no libido modification was observed. Increased BSP retention was observed in one third of patients.
Get full access to this article
View all access options for this article.
References
1.
CantinoT., GordanG. S.: High dosage delta 3-testolactone therapy of disseminated carcinoma of the breast.Cancer, 20: 458–463, 1967.
2.
Cooperative Breast Cancer Group:Testosterone propionate therapy in breast cancer.J.A.M.A., 168: 1069–1073, 1964.
3.
FalksonG., Van DikJ. J., Van EdenE. B., Van der MericeA. M., FalksonH. C.: Calusterone (NSC-88536): a poor substitute for fluoxymesterone (NSC-121665) in the treatment of advanced breast cancer.Cancer Chemother. Rep., 58: 939–941, 1974.
4.
GoldenbergI. S., WaltersM. W., RadvinR. S., AnsfieldF. J., SegaloffA.: Androgenic therapy advanced breast cancer in women.J.A.M.A., 223: 1267–1268, 1973.
5.
GordanG. S., HoldenA., WalterR. M.: Antitumor efficacy of 7-beta- 17-alfa-dimethyltestosterone (calusterone) in advanced female breast cancer.Calif. Med., 113: 1–10, 1970.
6.
GordanG. S., WesslerS., AvigliL. V.: Calusterone in the therapy for advanced breast cancer.J.A.M.A., 219: 483–490, 1972.
7.
SegaloffA.: Hormones and breast cancer.Recent Progr. Hormone Res., 22: 351–365, 1965.
